_800x533_L_1412520412.jpg)
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cerus Corporation (CERS)
The Cerus share price today is 2.830, view NASDAQ CERS stock exchange data. Track the latest Cerus share price with real-time updates on CERS stock performance including market cap, day range, 52-week range and dividend yield. Access CERS charts, earnings dates and analyst estimates to support your investment decisions.
2.830
-0.010(-0.35%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.770
2.860
52 wk Range
1.150
3.470
CERS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.7702.860
52 wk Range
1.1503.470
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CERS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
4.667
Upside
+64.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price movements are quite volatile
Form 144 CERUS CORPORATION For: 16 July- Investing.com
Cathie Wood’s ARK sells Deere stock, buys Rocket Lab- Investing.com
- Cathie Wood’s ARK sells Deere stock, buys Rocket Lab
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.667
(+64.90% Upside)
Cerus Corporation Earnings Call Summary for Q2/2026
- Cerus beat Q2 estimates with adjusted EPS loss of $0.01 vs. $0.03 expected and revenue of $63.3M, but shares fell 15.2% after hours on margin concerns.
- Product revenue rose 10% YoY to $57.4M; company raised FY 2026 guidance to $229M-$231M, projecting 11-12% growth driven by IFC and core platelet business.
- Gross margin declined to 51.4% from 55.2% YoY due to euro strength and inflation; operating cash flow negative $2.7M despite ninth straight positive EBITDA quarter.
- Management expects GAAP profitability ahead with INT200 device U.S. approval targeted for H1 2027 and Phase III RedeS trial results due Q4 2026.
- IFC franchise grew 40% excluding prior-year items to $6.7M; U.S. platelet penetration at two-thirds while IFC holds only 10% market share, signaling growth runway.
Last Updated: 31-07-2026, 02:48 am
Read Full TranscriptEarnings
Latest Release
30-07-2026
EPS / Forecast
-0.01 / -0.03
Revenue / Forecast
63.3M / 62.9M
Compare CERS to Peers and Sector
Metrics to compare | CERS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCERSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −83.3x | 11.6x | −0.4x | |
PEG Ratio | −1.29 | −0.10 | 0.00 | |
Price/Book | 8.1x | 2.5x | 2.6x | |
Price / LTM Sales | 2.6x | 2.6x | 3.1x | |
Upside (Analyst Target) | 75.7% | 101.9% | 48.4% | |
Fair Value Upside | Unlock | 25.3% | 6.5% | Unlock |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Cerus (CERS) Share Price Today?
The Cerus share price today is 2.830.
What is the current Cerus (CERS) share price and day range?
As of 14-08-2026, the Cerus share price is 2.830, with a previous close of 2.840. The share price has ranged from 2.770 to 2.860 today, while the 52-week range spans from 1.150 to 3.470.
What Is the Cerus Market Cap?
As of today, Cerus market cap is 571.320M.
What Is the Cerus (CERS) Share Price Target?
The average 12-month share price target for Cerus is 4.667, with a high estimate of 5 and a low estimate of 4. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +64.90% Upside potential.
What Is Cerus's Earnings Per Share (TTM)?
The Cerus EPS (TTM) is -0.035.
When Is the Next Cerus Earnings Date?
Cerus will release its next earnings report on 29-10-2026.
From a Technical Analysis Perspective, Is CERS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Cerus Trade On?
Cerus is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cerus?
The stock symbol for Cerus is "CERS."
How Many Times Has Cerus Stock Split?
Cerus has split 0 times.
How Many Employees Does Cerus Have?
Cerus has 268 employees.
What Is the CERS Premarket Price?
CERS's last pre-market stock price is 2.850. The pre-market share volume is 5,540.000, and the stock has changed by 0.010, or 0.350%.
What Is the CERS After Hours Price?
CERS's last after hours stock price is 2.860, the stock has changed by 0.020, or 0.700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.